Leerink Partnrs Weighs in on AnaptysBio FY2029 Earnings

AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) - Investment analysts at Leerink Partnrs issued their FY2029 earnings estimates for shares of AnaptysBio in a report released on Thursday, February 27th. Leerink Partnrs analyst D. Risinger anticipates that the biotechnology company will earn ($2.28) per share for the year. The consensus estimate for AnaptysBio's current full-year earnings is ($6.08) per share.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last issued its quarterly earnings data on Thursday, February 27th. The biotechnology company reported ($0.72) EPS for the quarter, beating the consensus estimate of ($1.61) by $0.89. The firm had revenue of $43.11 million during the quarter, compared to the consensus estimate of $10.17 million. AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.94%.

Several other research firms have also recently issued reports on ANAB. Truist Financial reduced their target price on AnaptysBio from $30.00 to $20.00 and set a "hold" rating on the stock in a research note on Wednesday, December 18th. BTIG Research downgraded shares of AnaptysBio from a "buy" rating to a "neutral" rating in a research report on Monday, December 2nd. HC Wainwright restated a "neutral" rating and issued a $22.00 price objective on shares of AnaptysBio in a report on Tuesday. Wedbush reaffirmed an "outperform" rating and set a $40.00 target price on shares of AnaptysBio in a research note on Wednesday, February 12th. Finally, Wolfe Research assumed coverage on shares of AnaptysBio in a research report on Tuesday, February 4th. They set an "outperform" rating and a $25.00 price target on the stock. Four investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $35.11.

Remove Ads

AnaptysBio Price Performance

NASDAQ:ANAB traded down $0.82 during mid-day trading on Monday, reaching $15.94. 192,333 shares of the company's stock traded hands, compared to its average volume of 1,045,237. The company has a 50 day moving average price of $16.11 and a 200-day moving average price of $24.27. The firm has a market capitalization of $484.89 million and a price-to-earnings ratio of -2.62. AnaptysBio has a 12-month low of $12.21 and a 12-month high of $41.31.

Insider Buying and Selling at AnaptysBio

In related news, Director Ecor1 Capital, Llc purchased 6,646 shares of AnaptysBio stock in a transaction dated Thursday, January 2nd. The stock was purchased at an average cost of $12.95 per share, for a total transaction of $86,065.70. Following the completion of the acquisition, the director now directly owns 7,880,094 shares of the company's stock, valued at $102,047,217.30. The trade was a 0.08 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 33.70% of the stock is owned by company insiders.

Institutional Trading of AnaptysBio

Several institutional investors have recently bought and sold shares of the company. Frazier Life Sciences Management L.P. raised its holdings in AnaptysBio by 2.0% in the third quarter. Frazier Life Sciences Management L.P. now owns 2,209,189 shares of the biotechnology company's stock worth $74,008,000 after buying an additional 43,598 shares during the last quarter. Point72 Asset Management L.P. raised its holdings in AnaptysBio by 202.8% in the 3rd quarter. Point72 Asset Management L.P. now owns 54,200 shares of the biotechnology company's stock worth $1,816,000 after acquiring an additional 36,300 shares during the last quarter. JPMorgan Chase & Co. lifted its position in AnaptysBio by 191.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 33,744 shares of the biotechnology company's stock valued at $1,130,000 after acquiring an additional 22,164 shares in the last quarter. Victory Capital Management Inc. boosted its stake in AnaptysBio by 677.9% during the 3rd quarter. Victory Capital Management Inc. now owns 237,250 shares of the biotechnology company's stock valued at $7,948,000 after purchasing an additional 206,750 shares during the last quarter. Finally, Verition Fund Management LLC bought a new stake in shares of AnaptysBio in the 3rd quarter worth $738,000.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.